Literature DB >> 23140198

A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia.

Vishwanath K Mahabir1, Catherine Ross, Snezana Popovic, Mona Lisa Sur, Jacqueline Bourgeois, Wendy Lim, James N George, Grace Wang, Richard J Cook, Lisa J Toltl, Ishac Nazi, John G Kelton, Donald M Arnold.   

Abstract

OBJECTIVE: The role of bone marrow examinations in patients with primary immune thrombocytopenia (ITP) is uncertain. The objectives of this study were to determine the inter-rater reliability of bone marrow examinations and to identify distinguishing morphological features of ITP bone marrows under controlled conditions.
METHODS: Histological slides of bone marrow biopsy specimens and aspirates from 32 adult patients with severe primary ITP who had failed a median of two treatments, and 51 non-thrombocytopenic controls were retrieved from hospital archives. Slides were arranged in random order in a slide box and coded. Blinded to the diagnosis and platelet counts, three independent hematopathologists were asked to identify the ITP bone marrows and to evaluate megakaryocyte number, morphology, and distribution.
RESULTS: Overall chance-corrected agreement on ITP classification among the three raters was poor [kappa (κ) = 0.30; 95% confidence interval 0.22-0.38]. Raters were generally unable to correctly identify the ITP bone marrows from controls. Increased number of megakaryocytes, while an uncommon finding, was more frequent among ITP patients compared with controls (6/32, 18.8%; vs. 2/51, 3.9%; P = 0.05), and abnormal megakaryocyte morphology often led individual raters to reach a diagnosis of ITP. Overall sensitivity and specificity of bone marrow examinations were 24% and 90%, respectively.
CONCLUSIONS: This study confirms methodologically that bone marrow examinations are unreliable and frequently non-diagnostic in ITP. Thus, they are not useful for patients with typical disease. Rare subsets of patients with severe ITP demonstrated unique features such as increased number of megakaryocytes.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 23140198      PMCID: PMC3938453          DOI: 10.1111/ejh.12041

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  22 in total

1.  Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

Authors:  Robert McMillan; Lei Wang; Aaron Tomer; Janet Nichol; Jeanne Pistillo
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

2.  The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism.

Authors:  W DAMESHEK; E B MILLER
Journal:  Blood       Date:  1946-01       Impact factor: 22.113

3.  A study of the bone marrow from 36 patients with idiopathic hemorrhagic, thrombopenic purpura.

Authors:  L W DIGGS; J S HEWLETT
Journal:  Blood       Date:  1948-10       Impact factor: 22.113

4.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

5.  Idiopathic thrombocytopenic purpura; a study of three cases with special reference to changes in the megakaryocytes.

Authors:  E H VALENTINE
Journal:  Am J Med Sci       Date:  1947-09       Impact factor: 2.378

6.  Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia?

Authors:  C Calpin; P Dick; A Poon; W Feldman
Journal:  Arch Pediatr Adolesc Med       Date:  1998-04

7.  Thrombokinetics in idiopathic thrombocytopenic purpura.

Authors:  L A Harker
Journal:  Br J Haematol       Date:  1970-07       Impact factor: 6.998

Review 8.  The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review.

Authors:  Steven J Jubelirer; Robert Harpold
Journal:  Clin Appl Thromb Hemost       Date:  2002-01       Impact factor: 2.389

9.  Megakaryocytopoiesis in idiopathic thrombocytopenic purpura: a morphometric and immunohistochemical study on bone marrow biopsies with special emphasis on precursor cells.

Authors:  J Thiele; E von Ammers; S Wagner; C Degel; R Fisher
Journal:  Hematol Pathol       Date:  1991

Review 10.  Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.

Authors:  Diane Nugent; Robert McMillan; Janet L Nichol; Sherrill J Slichter
Journal:  Br J Haematol       Date:  2009-05-14       Impact factor: 6.998

View more
  8 in total

1.  Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia.

Authors:  Donald M Arnold; Ishac Nazi; Lisa J Toltl; Catherine Ross; Nikola Ivetic; James W Smith; Yang Liu; John G Kelton
Journal:  Eur J Haematol       Date:  2015-03-13       Impact factor: 2.997

2.  Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia.

Authors:  Thibault Comont; Johanne Germain; Odile Beyne-Rauzy; Daniel Adoue; Guillaume Moulis
Journal:  Blood Adv       Date:  2020-05-26

3.  Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia.

Authors:  Min Wang; Ru Feng; Jia-Min Zhang; Lin-Lin Xu; Fei-Er Feng; Chen-Cong Wang; Qian-Ming Wang; Xiao-Lu Zhu; Yun He; Jing Xue; Hai-Xia Fu; Meng Lv; Yuan Kong; Ying-Jun Chang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-05-14

4.  Re-evaluation of Need for Bone Marrow Examination in Patients with Isolated Thrombocytopenia Contributors.

Authors:  Abhishek Purohit; Mukul Aggarwal; Pawan Kumar Singh; Manoranjan Mahapatra; Tulika Seth; Seema Tyagi; Renu Saxena; Hara P Pati; Pravas Mishra
Journal:  Indian J Hematol Blood Transfus       Date:  2015-03-28       Impact factor: 0.900

5.  Serum Thrombopoietin and cMpl Expression in Thrombocytopenia of Different Etiologies.

Authors:  Fabrizio Vianello; Silvia Vettore; Fabiana Tezza; Luca De Toni; Raffaella Scandellari; Luisa Sambado; Martina Treleani; Fabrizio Fabris
Journal:  Hematol Rep       Date:  2014-03-26

6.  Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases.

Authors:  Brian Eyden; Yong-Xin Ru; Shu-Xu Dong; Jing Liu; Xiao-Fan Liu
Journal:  Blood Sci       Date:  2021-10-13

7.  Evaluation of thrombocytopenia in the hematology clinic: a case series from a large tertiary care center.

Authors:  Aishwarya Ravindran; Ronald S Go; Kaaren K Reichard; Ariela L Marshall
Journal:  Blood Res       Date:  2018-06-25

8.  Protective Effect of Royal Jelly against Cyclophosphamide-Induced Thrombocytopenia and Spleen and Bone Marrow Damages in Rats.

Authors:  Fatemeh Khazaei; Elham Ghanbari; Mozafar Khazaei
Journal:  Cell J       Date:  2019-12-15       Impact factor: 2.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.